IndiaTuberculosis profile
Population  2017 1 339 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 410 (380–440) 31 (28–33)
Mortality (HIV+TB only) 11 (6.5–16) 0.79 (0.48–1.2)
Incidence  (includes HIV+TB) 2 740 (1 870–3 770) 204 (140–281)
Incidence (HIV+TB only) 86 (57–120) 6.4 (4.3–9)
Incidence (MDR/RR-TB)** 135 (78–208) 10 (5.8–16)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 107 (100–114) 847 (684–1 010) 954 (759–1 150)
Males 117 (109–126) 1 670 (1 220–2 120) 1 780 (1 290–2 280)
Total 224 (202–247) 2 510 (1 680–3 350) 2 740 (1 870–3 770)
TB case notifications, 2017  
Total cases notified 1 908 371
Total new and relapse 1 786 681
          - % tested with rapid diagnostics at time of diagnosis 40%
          - % with known HIV status 64%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 60%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 65% (47–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.16 (0.11–0.22)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 36 440 3%
          - on antiretroviral therapy 28 651 79%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  65 000
(54 000–76 000)
Estimated % of TB cases with MDR/RR-TB 2.8% (2–3.5) 12% (10–13)  
% notified tested for rifampicin resistance 32% 82% 720 051
MDR/RR-TB cases tested for resistance to second-line drugs   26 832
Laboratory-confirmed cases MDR/RR-TB: 39 009, XDR-TB: 2 650
Patients started on treatment **** MDR/RR-TB: 35 950, XDR-TB: 2 838
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 69% 1 763 876
Previously treated cases, excluding relapse, registered in 2016 70% 172 282
HIV-positive TB cases registered in 2016 75% 39 123
MDR/RR-TB cases started on second-line treatment in 2015 46% 26 966
XDR-TB cases started on second-line treatment in 2015 28% 2 130
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
11% (10–12)
TB financing, 2018  
National TB budget (US$ millions) 580
Funding source: 79% domestic, 21% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-24 Data: www.who.int/tb/data